Larry Goldstein to Anticholesteremic Agents
This is a "connection" page, showing publications Larry Goldstein has written about Anticholesteremic Agents.
Connection Strength
1.774
-
Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2023 10; 43(10):e404-e442.
Score: 0.801
-
Statins after intracerebral hemorrhage: to treat or not to treat. Arch Neurol. 2011 May; 68(5):565-6.
Score: 0.333
-
Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology. 2008 Jun 10; 70(24 Pt 2):2364-70.
Score: 0.269
-
Prediction of major vascular events after stroke: the stroke prevention by aggressive reduction in cholesterol levels trial. J Stroke Cerebrovasc Dis. 2014 Apr; 23(4):778-84.
Score: 0.103
-
Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial. Stroke. 2009 Jul; 40(7):2486-92.
Score: 0.074
-
Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke. 2009 Apr; 40(4):1405-9.
Score: 0.073
-
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. Neurology. 2009 Feb 24; 72(8):688-94.
Score: 0.071
-
Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks: Results of an Analysis of 13 Biomarkers From the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial. Stroke. 2017 12; 48(12):3223-3231.
Score: 0.033
-
Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2007 Dec; 38(12):3198-204.
Score: 0.017